PMID- 23363269
OWN - NLM
STAT- MEDLINE
DCOM- 20140508
LR  - 20190116
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 54
IP  - 10
DP  - 2013 Oct
TI  - MYC rearrangements are useful for predicting outcomes following rituximab and 
      chemotherapy: multicenter analysis of Japanese patients with diffuse large B-cell 
      lymphoma.
PG  - 2149-54
LID - 10.3109/10428194.2013.771398 [doi]
AB  - Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin 
      lymphoma, and it has several morphologic and clinicopathologic variants. The 
      prognosis of DLBCL can vary according to specific genetic and immunophenotypic 
      abnormalities. The aim of this study was to investigate the prognostic impact of 
      previously identified prognostic factors, such as activated B cell-like 
      immunophenotype, CD5, BCL2 and MYC rearrangement (MYC-R), in patients treated 
      with rituximab. We retrospectively analyzed the prognosis of 100 patients with 
      DLBCL (median age, 66.5 years) treated with rituximab-containing chemotherapy. 
      The 3-year overall survival (OS) and progression-free survival (PFS) were 66% and 
      62%. Outcomes were significantly worse in patients with MYC-R in 3-year OS (50% 
      vs. 67.8%, p = 0.043) and PFS (30% vs. 57.8%, p = 0.003), and multivariate 
      analysis showed that this finding was independent of the International Prognostic 
      Index (IPI). Immunostaining by Muris algorithm had the highest predictive power 
      among the three algorithms. However, other previously reported prognostic 
      factors, such as BCL2 and CD5, were not good predictors of outcomes in these 
      patients. In conclusion, our data suggest that fluorescence in situ hybridization 
      (FISH) analysis for MYC-R can predict outcomes in response to 
      rituximab-containing chemotherapy in Japanese patients with DLBCL.
FAU - Kojima, Minoru
AU  - Kojima M
AD  - Division of Hematology/Oncology, Department of Internal Medicine.
FAU - Nishikii, Hidekazu
AU  - Nishikii H
FAU - Takizawa, Jun
AU  - Takizawa J
FAU - Aoki, Sadao
AU  - Aoki S
FAU - Noguchi, Masayuki
AU  - Noguchi M
FAU - Chiba, Shigeru
AU  - Chiba S
FAU - Ando, Kiyoshi
AU  - Ando K
FAU - Nakamura, Naoya
AU  - Nakamura N
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20130308
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Antibodies, Monoclonal, Murine-Derived)
RN  - 4F4X42SYQ6 (Rituximab)
SB  - IM
CIN - Leuk Lymphoma. 2013 Oct;54(10):2091-2. PMID: 24041377
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibodies, Monoclonal, Murine-Derived/administration & dosage
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Female
MH  - *Gene Rearrangement
MH  - *Genes, myc
MH  - Humans
MH  - Immunophenotyping
MH  - In Situ Hybridization, Fluorescence
MH  - Lymphoma, Large B-Cell, Diffuse/*drug therapy/*genetics/mortality/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Rituximab
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2013/02/01 06:00
MHDA- 2014/05/09 06:00
CRDT- 2013/02/01 06:00
PHST- 2013/02/01 06:00 [entrez]
PHST- 2013/02/01 06:00 [pubmed]
PHST- 2014/05/09 06:00 [medline]
AID - 10.3109/10428194.2013.771398 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2013 Oct;54(10):2149-54. doi: 10.3109/10428194.2013.771398. Epub 
      2013 Mar 8.